Dr. Richard Heinzl, Physician, Humanitarian, Entrepreneur, and Author, Appointed to Asep Inc. Board of Directors

VANCOUVER, BC, September 29, 2022 /PRNewswire/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce the appointment of Dr. Richard Heinzl to the Company’s Board of Directors effective immediately.

Dr. Heinzl is a physician, humanitarian, entrepreneur, and author who currently focuses on genomics, artificial intelligence, and healthcare worldwide. Based in New York and Toronto, he is currently CEO of My Next Health Inc., a next-generation functional genomics company.

Earlier in his career, Dr. Heinzl was the founder of the Canadian chapter of Médecins Sans Frontières/Médecins Sans Frontières (MSF Canada), which won the Nobel Peace Prize in 1999. Recently, he served as Global Medical Director for WorldCare Inc., a Boston-based, Harvard-affiliated Virtual Medicine Society. He is a graduate of the Michael G. DeGroote School of Medicine at McMaster University and has completed postgraduate degrees related to global health at Harvard University and the University of Oxford. He is a Fellow Emeritus of the American College of Preventive Medicine. His work and travels have taken him to over 80 countries, and he speaks widely in North America and abroad. In 2000, he received an Honorary Doctorate (LLD) from his alma mater McMaster University and was named one of Canada’s “One Hundred People Making a Difference” by Penguin Books. In September 2016, he received the Harvard TH Chan School of Public Health Alumni Achievement Award, the school’s highest honor.

Dr Heinzl said: “I am very honored to be part of the Asep team under the visionary scientific leadership of Bob Hancock. It’s really exciting to see how biotechnology has enormous potential to change the paradigm of human health care.

“Having a world-class physician and entrepreneur on our board will help us address the unmet medical needs in major unmet markets associated with antibiotic failure,” said Robert EW Hancock. , CEO and co-founder of Asep. “Richard will bring a strong medical and global perspective to the board.”


Asep Medical Inc. (asepmedical.com) is dedicated to solving antibiotic failure by developing new solutions for significant unmet medical needs. The company is a consolidation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.) which are both in the advanced development of the two proprietary diagnostic tools, enabling the early and rapid identification of severe sepsis as well as broad-spectrum therapies. agents for combating multidrug resistant biofilm infections.

Sepset Biosciences Inc. (sepset.ca) is developing diagnostic technology that involves a patient’s gene expression signature that predicts severe sepsis, one of the important diseases leading to antibiotic failure, since antibiotics are the primary sepsis treatment. Despite this, sepsis is responsible for almost 20% of all deaths on the planet. The SepsetER test is a blood-based gene expression test that is simple to perform, and results are obtained in approximately one hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in that it can diagnose severe sepsis within 1-2 hours of first clinical presentation (i.e. in the emergency room), while other diagnostics provide a diagnosis only after 24 to 36 hours. Asep Inc. believes this will enable physicians to make critical early decisions about appropriate treatments and reduce overall morbidity and mortality from sepsis.

ABT Innovations Inc. (abtinnovations.ca) peptide technology covers a wide range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, ear -nose-throat, sinusitis, orthopedics, etc.), anti-inflammatories, anti-infective immunomodulators and vaccine adjuvants.


This press release contains certain “forward-looking statements” within the meaning of such statements under applicable securities laws. Forward-looking statements are often characterized by words such as “expects”, “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “expects”, ” believes”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will occur”. These statements include, but are not limited to, the successful completion of clinical testing of our Sepsis diagnostic test and its anticipated filing for regulatory approval; and conducting preclinical studies on our lead drug, in the hope that this will lead to accelerated clinical trials. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management as of the date the statements are made and are subject to a variety of risks (including the risk factors identified in Asep Medical Inc.’s prospectus dated November 9, 2021) available for review under the company’s profile at www.sedar.com and the uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Asep Medical Inc. is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. applicable expressly so requires.

Asep Medical Holdings Inc. (CNW Group/ASEP Medical Holdings Inc.)

Quote View original content to download multimedia: https://www.prnewswire.com/news-releases/dr-richard-heinzl-physician-humanitarian-entrepreneur-and-author-appointed-to-asep-incs-board-of -directors-301637346.html

SOURCEASEP Medical Holdings Inc.